Logo image of FRX.CA

FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Fundamental Analysis

Canada - TSX:FRX - CA31447P1009 - Common Stock

12.17 CAD
-0.28 (-2.25%)
Last: 11/18/2025, 7:00:00 PM
Fundamental Rating

2

Overall FRX gets a fundamental rating of 2 out of 10. We evaluated FRX against 21 industry peers in the Biotechnology industry. FRX has a bad profitability rating. Also its financial health evaluation is rather negative. FRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FRX has reported negative net income.
FRX had a negative operating cash flow in the past year.
In the past 5 years FRX always reported negative net income.
FRX had negative operating cash flow in 4 of the past 5 years.
FRX.CA Yearly Net Income VS EBIT VS OCF VS FCFFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

The Return On Assets of FRX (-26.83%) is better than 76.19% of its industry peers.
Industry RankSector Rank
ROA -26.83%
ROE N/A
ROIC N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FRX.CA Yearly ROA, ROE, ROICFRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

FRX's Gross Margin of 89.89% is amongst the best of the industry. FRX outperforms 100.00% of its industry peers.
The Profit Margin and Operating Margin are not available for FRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRX.CA Yearly Profit, Operating, Gross MarginsFRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, FRX has more shares outstanding
FRX has more shares outstanding than it did 5 years ago.
FRX has a better debt/assets ratio than last year.
FRX.CA Yearly Shares OutstandingFRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FRX.CA Yearly Total Debt VS Total AssetsFRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -3.32, we must say that FRX is in the distress zone and has some risk of bankruptcy.
FRX has a Altman-Z score (-3.32) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.32
ROIC/WACCN/A
WACCN/A
FRX.CA Yearly LT Debt VS Equity VS FCFFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

FRX has a Current Ratio of 4.85. This indicates that FRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of FRX (4.85) is better than 71.43% of its industry peers.
FRX has a Quick Ratio of 4.59. This indicates that FRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of FRX (4.59) is better than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 4.85
Quick Ratio 4.59
FRX.CA Yearly Current Assets VS Current LiabilitesFRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

FRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -520.00%.
FRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -31.89%.
EPS 1Y (TTM)-520%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
Revenue 1Y (TTM)-31.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.91%

3.2 Future

The Earnings Per Share is expected to grow by 240523.00% on average over the next years. This is a very strong growth
FRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.44% yearly.
EPS Next Y-132665236383229020%
EPS Next 2Y10894974643.37%
EPS Next 3Y26121300%
EPS Next 5Y240523%
Revenue Next Year-21.01%
Revenue Next 2Y14.09%
Revenue Next 3Y15.4%
Revenue Next 5Y24.44%

3.3 Evolution

FRX.CA Yearly Revenue VS EstimatesFRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FRX.CA Yearly EPS VS EstimatesFRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FRX. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 13.17 indicates a correct valuation of FRX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FRX indicates a rather cheap valuation: FRX is cheaper than 95.24% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.98. FRX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 13.17
FRX.CA Price Earnings VS Forward Price EarningsFRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRX.CA Per share dataFRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

FRX's earnings are expected to grow with 26121300.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10894974643.37%
EPS Next 3Y26121300%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

TSX:FRX (11/18/2025, 7:00:00 PM)

12.17

-0.28 (-2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners56.74%
Inst Owner ChangeN/A
Ins Owners2.21%
Ins Owner ChangeN/A
Market Cap338.69M
Revenue(TTM)33.30M
Net Income(TTM)-12.04M
Analysts85.45
Price Target19.81 (62.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.86%
Min EPS beat(2)-199.56%
Max EPS beat(2)55.84%
EPS beat(4)1
Avg EPS beat(4)-101.98%
Min EPS beat(4)-199.56%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-153.59%
EPS beat(12)4
Avg EPS beat(12)-110.94%
EPS beat(16)6
Avg EPS beat(16)-92.6%
Revenue beat(2)1
Avg Revenue beat(2)2.15%
Min Revenue beat(2)-0.57%
Max Revenue beat(2)4.87%
Revenue beat(4)1
Avg Revenue beat(4)-18.28%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)4.87%
Revenue beat(8)4
Avg Revenue beat(8)-6.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.9%
PT rev (3m)14.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-121.4%
EPS NY rev (1m)-278.71%
EPS NY rev (3m)-142.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.51%
Revenue NY rev (1m)-4.68%
Revenue NY rev (3m)-5.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.17
P/S 7.25
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)0.92
Fwd EY7.59%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS1.68
BVpS-0.38
TBVpS-0.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.83%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.89%
FCFM N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.85
Quick Ratio 4.59
Altman-Z -3.32
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-520%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
EPS Next Y-132665236383229020%
EPS Next 2Y10894974643.37%
EPS Next 3Y26121300%
EPS Next 5Y240523%
Revenue 1Y (TTM)-31.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.91%
Revenue Next Year-21.01%
Revenue Next 2Y14.09%
Revenue Next 3Y15.4%
Revenue Next 5Y24.44%
EBIT growth 1Y-258.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2497.85%
EBIT Next 3Y306.35%
EBIT Next 5YN/A
FCF growth 1Y43.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.63%
OCF growth 3YN/A
OCF growth 5YN/A

FENNEC PHARMACEUTICALS INC / FRX.CA FAQ

What is the ChartMill fundamental rating of FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to FRX.CA.


Can you provide the valuation status for FENNEC PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 3 / 10 to FENNEC PHARMACEUTICALS INC (FRX.CA). This can be considered as Overvalued.


What is the profitability of FRX stock?

FENNEC PHARMACEUTICALS INC (FRX.CA) has a profitability rating of 1 / 10.


How financially healthy is FENNEC PHARMACEUTICALS INC?

The financial health rating of FENNEC PHARMACEUTICALS INC (FRX.CA) is 3 / 10.